Latest Leadership News

Emu NL has reported promising visible copper sulphide mineralisation from its maiden drilling at Fiery Creek, advancing its Georgetown copper-gold project. Meanwhile, the company navigates leadership changes and governance reviews amid ongoing exploration.

Alterity Therapeutics has bolstered its Phase 2 data for ATH434 in Multiple System Atrophy and is advancing regulatory plans for a pivotal Phase 3 trial, supported by a robust cash position of A$49.2 million.

KGL Resources has secured A$11 million to accelerate development at its Jervois Copper-Silver-Gold Project, buoyed by soaring commodity prices and fresh leadership appointments. The company is progressing construction readiness and optimisation efforts while engaging with funding partners.

Antares Metals has strategically acquired two Western Australian gold and copper projects while uncovering a significant high-grade copper zone at its Mt Isa North project, backed by a $2 million capital raise and new leadership.

Rapid Critical Metals has validated historic high-grade gallium and germanium mineralisation at its Prophet River Project in British Columbia, identifying five promising drill targets through advanced geophysical surveys.

Stakk Limited has reported a robust Q2FY26 with record cash receipts and a fortified $15.1 million cash reserve, setting the stage for breakeven in CY26 amid strong Tier-1 client momentum.

Estrella Resources has reported multiple high-grade manganese intersections at its Ira Miri project, including assays up to 58% manganese, and received regulatory approval for a 30,000-tonne bulk sample extraction. Concurrently, drilling at the Werumata limestone project has been completed with assay results pending.

Pacific Lime and Cement Limited reports steady progress on its Central Lime Project in Papua New Guinea, securing key government agreements and strategic partnerships while maintaining financial discipline.

BluGlass Limited has extended its contract with the U.S. Department of War by A$1.05 million and appointed a refreshed Board to accelerate its commercial growth in visible laser technology. The company is advancing its GaN laser portfolio amid a US$100 million project pipeline and ongoing R&D investments.

Actinogen Medical’s pivotal XanaMIA trial for Alzheimer’s disease has received a green light from its independent Data Monitoring Committee to continue, reinforcing confidence in the drug’s safety and efficacy profile.

Atomic Eagle Limited has announced a substantial uranium exploration target at its Muntanga Project in Zambia, supported by promising drilling results that suggest significant resource expansion potential.

HeraMED has secured pivotal US commercial agreements and achieved a key Australian regulatory milestone, positioning itself for scalable growth in digital maternity care.